"Complement C5a" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The minor fragment formed when C5 convertase cleaves C5 into C5a and COMPLEMENT C5B. C5a is a 74-amino-acid glycopeptide with a carboxy-terminal ARGININE that is crucial for its spasmogenic activity. Of all the complement-derived anaphylatoxins, C5a is the most potent in mediating immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE), smooth MUSCLE CONTRACTION; HISTAMINE RELEASE; and migration of LEUKOCYTES to site of INFLAMMATION.
Descriptor ID |
D015936
|
MeSH Number(s) |
D12.776.124.486.274.024.270 D12.776.124.486.274.450.250
|
Concept/Terms |
Complement C5a- Complement C5a
- C5a, Complement
- C5a Complement
- Complement, C5a
- Complement Component 5a
- Component 5a, Complement
- Complement 5a
|
Below are MeSH descriptors whose meaning is more general than "Complement C5a".
Below are MeSH descriptors whose meaning is more specific than "Complement C5a".
This graph shows the total number of publications written about "Complement C5a" by people in this website by year, and whether "Complement C5a" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Complement C5a" by people in Profiles.
-
Altered expression of CD88 and associated impairment of complement 5a-induced neutrophil responses in human immunodeficiency virus type 1-infected patients with and without pulmonary tuberculosis. J Infect Dis. 2001 Feb 15; 183(4):662-5.
-
Defective neutrophil degranulation induced by interleukin-8 and complement 5a and down-regulation of associated receptors in children vertically infected with human immunodeficiency virus type 1. Clin Diagn Lab Immunol. 2001 Jan; 8(1):21-30.